Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of approximately 5,000. As with the other low molecular weight heparins, dalteparin has certain advantages over unfractionated heparin (UFH) most important of which are improved bio-availability by subcutaneous injection, a prolonged antithrombotic activity which is highly correlated with body weight permitting the once daily administration of the drug. Other possible advantages of LMWH including dalteparin include a lower incidence of heparin induced thrombocytopenia and thrombosis and decreased tendency to produce osteopenia on prolonged administration. Dalteparin has been subjected to a large number of well designed randomised clinical trials for the prevention and treatment of venous thromboembolism. Based on data from the randomised clinical trials, dalteparin has been approved internationally for a wide spectrum of clinical indications.
Pineo
Graham F
GF
University of Calgary, Thrombosis Research Unit, Foothills Hospital, Calgary, AB, Canada.
Hull
Russell D
RD
D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications; D017985:Dalteparin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008970:Molecular Weight; D009369:Neoplasms / Q000188:drug therapy / Q000601:surgery; D013514:Surgical Procedures, Operative; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017985:Dalteparin